source
- FDA approves Egetis Therapeutics' Emcitate for rare X linked disease shortening life expectancy to 35 yearsEgetis Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its drug Emcitate. The therapy is intended for patients with a rare X linked genetic disorder that…
- Beam Therapeutics sues former scientist over alleged IP theft to launch Chinese biotech YolTechBeam Therapeutics, a Cambridge‑based gene‑editing company, has filed a lawsuit accusing a former scientist of stealing proprietary data. The complaint says Zi Jun "Emma" Wang accessed Beam's elect…